Lung cancer: diagnosis and management

Supporting evidence

• Surveillance report

• 2021 exceptional surveillance of HIV indicator conditions (NICE guidelines NG52, CG153, NG122 and NG203)

• 2021 exceptional surveillance of lung cancer: diagnosis and management (NICE guideline NG122)

• 2020 exceptional surveillance of lung cancer: diagnosis and management (NICE guideline NG122) and colorectal cancer (NICE guideline NG151)

• 2019 exceptional surveillance of lung cancer: diagnosis and management (NICE guideline NG122) 

• Appendix A: Summary of evidence from surveillance (PDF 425 KB)

  Published:

  06 June 2019

• Surveillance report 2016 – Lung cancer (2011) NICE guideline CG121

• Appendix A: Decision matrix (PDF 1.02 MB)

  Published:

  17 March 2016

• Evidence review

• Evidence reviews – March 2019

• A: Effectiveness of non-ultrasound-guided TBNA, EBUS-TBNA or EUS-FNA for people with a probability of mediastinal malignancy (PDF 1.15 MB)

  Published:

  28 March 2019

• B: Clinical and cost-effectiveness of routine MRI or CT of the brain in the management of people with lung cancer prior to therapy with curative intent (PDF 4.14 MB)

  Published:

  28 March 2019

• C: Clinical and cost effectiveness of treatment regimen for the treatment of operable Stage IIIA-N2 NSCLC (PDF 2.77 MB)

  Published:

  28 March 2019

• D: Clinical and cost effectiveness of different radiotherapy regimens with curative intent for NSCLC (PDF 2.19 MB)

  Published:

  28 March 2019

• E: Development of a systemic anti-cancer therapy algorithm (PDF 460 KB)

  Published:

  28 March 2019

• F: Most clinically and cost-effective regimen of chemoradiotherapy for people with limited-stage SCLC (PDF 847 KB)

  Published:

  28 March 2019

• G: Clinical and cost-effectiveness of first use of thoracic radiotherapy for people with extensive-stage SCLC who have had first-line treatment with systemic anti-cancer therapies (PDF 812 KB)

  Published:

  28 March 2019

• H: Clinical and cost-effectiveness of prophylactic cranial irradiation to prevent brain metastases in people with extensive SCLC (PDF 931 KB)

  Published:

  28 March 2019

• Full guidance

• Full guideline – April 2011

• Full guideline (PDF 6.79 MB)

  Published:

  21 April 2011